Hip Resurfacing Arthroplasty (HRA) has been performed in the United States for over 10 years and is an alternative to standard Total Hip Arthropastly (THA). It is appealing to younger patients with end stage osteoarthritis who seek to maintain active lifestyles. Benefits of HRA versus THR include a larger femoral ball size, potential to return to impact activities, decreased dislocation rates, and restoration of normal hip biomechanics. Patients ≤50 years old are a particularly challenging patient group to treat with THA because of their young age and high activity level, and as such, are well-suited for HRA. However, there are limited reports in the literature about clinical, radiographic and functional outcomes for this patient cohort. We present results of a clinical investigation at our institution for this patient cohort with minimum 5-year follow up, including long term survivorship and outcome scores. HRA, using the Birmingham Hip Resurfacing (BHR), was performed for 538 procedures between 2006–2009 by a single surgeon at a United States teaching hospital. After Institutional Review Board approval, medical and radiographic study records were retrospectively reviewed. Harris Hip Scores (HHS) were routinely collected. Patients who had not returned for follow-up examination were contacted by telephone for information pertaining to their status and implant, and a modified HHS was also administered. A Kaplan Meier survival curve was constructed to evaluate time to revision. Statistical analysis was performed (SAS version 9.3; SAS Institute, Cary, NC).Introduction
Methods
Patients presenting with osteoarthritis as late sequelae following pediatric hip trauma have few options aside from standard Total Hip Replacement (THR). For younger more active patients, Hip Resurfacing Arthroplasty (HRA) can be offered as an alternative. HRA has been performed in the United States over the past decade and allows increased bone preservation, decreased hip dislocation rates versus THR, and potential to return to full activities. Patients presenting with end-stage hip arthritis as following prior pediatric trauma or disease often have altered hip morphology making HRA more complicated. Often Legg-Calve-Perthes (LCP) patients present with short, wide femoral necks, and femoral head distortion including coxa magna or coxa plana. There often can be acetabular dysplasia in conjunction with the proximal femoral abnormalities. Slipped Capital Femoral Epiphysis (SCFE) patients have an alteration of the femoral neck and head alignment, which can make reshaping the femoral head difficult. In particular, the femoral head is rotated medially and posteriorly, reducing the anterior and lateral offset. We present a cohort of 20 patients, with history of a childhood hip disorder (SCFE or LCP), who underwent HRA to treat end-stage arthritis. Fifty percent had prior pediatric surgical intervention at an average age of 11. After Institutional Review Board approval, data was reviewed retrospectively on patients with pediatric hip diseases of SCFE and LCP who underwent HRA using the Birmingham Hip Resurfacing (BHR) by a single orthopaedic surgeon at a teaching institution. Harris Hip Scores (HHS), plain radiographs and blood metal ion levels were reviewed at routine intervals (12 months and annually thereafter). Those who had not returned for recent follow-up were contacted via telephone survey for a modified HHS.Introduction
Method
During the last ten years, greater attention
has been given to the management of peri-operative blood loss after
total knee arthroplasty (TKA), as it is a modifiable outcome that has
a significant effect on the rate of complications, the recovery,
and the economic burden. Blood loss after TKA has been greatly reduced
during this time, thereby dramatically reducing the rates of allogeneic
transfusion. This has significantly reduced the complications associated
with transfusion, such as fluid overload, infection, and increased length
of stay. The greatest advent in lowering peri-operative blood loss after
TKA has been the introduction of tranexamic acid, which reduces
blood loss without increasing the risk of thromboembolic events. This paper discusses the ways of reducing blood loss after TKA,
for which a multimodal algorithm, with pre-, intra- and post-operative
measures, has been adopted at our institution. Cite this article:
